Renal cell carcinoma with fibromyomatous stroma, recognized as a provisional entity in the current 2022 World Health Organization classification of renal neoplasms, is rare. Recent evidence suggests recurrent alterations in the mTOR pathway, supporting its recognition as a distinct entity. Herein, we report 2 renal cell carcinomas with fibromyomatous stroma with MTOR mutations occurring in 62- and 72-year-old women and review the literature to support its recognition as a distinct entity, focusing on the characteristic morphology, immunohistochemical staining patterns as well as genetic alterations.
International journal of surgical pathology. 2024 Feb 04 [Epub ahead of print]
Ejas Palathingal Bava, Nilesh Gupta, Fatimah I Alruwaii, Ryan Nelson, Khaleel I Al-Obaidy
Department of Pathology and Laboratory Medicine, Henry Ford Health, Detroit, MI, USA., Department of Urology, Henry Ford Health, Detroit, MI, USA.